Akorn Receives Second Warning Letter This Year

Drug Industry Daily
A A
The FDA hit Illinois-based generic drugmaker Akorn with an extensive warning letter for violations at its Somerset, New Jersey facility — the company’s second warning of the year.

To View This Article:

Login

Subscribe To Drug Industry Daily